Collaboration Agreements	3 Months Ended
Mar. 31, 2012
Collaboration Agreements Disclosure [Abstract]
Collaboration Agreements	9. Collaboration Agreements Abbott Laboratories In August 2009, Trubion Pharmaceuticals, Inc. (“Trubion”), which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott, for the joint worldwide development and commercialization of TRU-016. The collaboration agreement covered TRU-016 in all indications and all other CD37-directed protein therapeutics. The collaboration agreement terminated on March 20, 2012 and all rights to TRU-016 and other CD37-directed protein therapeutics under the collaboration agreement reverted to the Company. During the three months ended March 31, 2012 and 2011, the Company recognized revenue of $1.3 million and $2.5 million, respectively, for research and development services pursuant to the Abbott collaboration in the Company’s statements of operations as contracts and grants revenue. Pfizer Inc. In December 2005, Trubion entered into an agreement (the “Pfizer Agreement”) with Wyeth, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In May 2011, the Company and Pfizer entered into a third amendment to the Pfizer Agreement (the “Biosimilar Amendment”) in which the Company released certain restrictions related to the development and commercialization of biosimilar CD20 antibodies. Under the terms of this amendment, the Company received a $2.5 million non-refundable payment upon execution of the Biosimilar Amendment, and is entitled to receive royalty payments in the low-single digits on net sales of certain Pfizer biosimilar products directed to CD20, subject to the satisfaction of specified conditions. In April 2012, Pfizer informed the Company of its intent to terminate the Pfizer Agreement. The Company’s right to receive these biosimilar royalty payments would survive a termination of the Pfizer Agreement. For the three months ended March 31, 2012 and 2011, the Company recognized revenue of $365,000 and $551,000, respectively, for research and development services pursuant to the Pfizer Agreement in the Company’s financial statements of operations as contracts and grants revenue.

In August 2009, Trubion Pharmaceuticals, Inc. (“Trubion”), which the Company acquired in October 2010, entered into a collaboration agreement with Facet Biotech Corporation, now a wholly-owned subsidiary of Abbott, for the joint worldwide development and commercialization of TRU-016. The collaboration agreement covered TRU-016 in all indications and all other CD37-directed protein therapeutics. The collaboration agreement terminated on March 20, 2012 and all rights to TRU-016 and other CD37-directed protein therapeutics under the collaboration agreement reverted to the Company.

During the three months ended March 31, 2012 and 2011, the Company recognized revenue of $1.3 million and $2.5 million, respectively, for research and development services pursuant to the Abbott collaboration in the Company’s statements of operations as contracts and grants revenue.

In December 2005, Trubion entered into an agreement (the “Pfizer Agreement”) with Wyeth, now a wholly-owned subsidiary of Pfizer, for the development and worldwide commercialization of CD20-directed therapeutics. In May 2011, the Company and Pfizer entered into a third amendment to the Pfizer Agreement (the “Biosimilar Amendment”) in which the Company released certain restrictions related to the development and commercialization of biosimilar CD20 antibodies. Under the terms of this amendment, the Company received a $2.5 million non-refundable payment upon execution of the Biosimilar Amendment, and is entitled to receive royalty payments in the low-single digits on net sales of certain Pfizer biosimilar products directed to CD20, subject to the satisfaction of specified conditions. In April 2012, Pfizer informed the Company of its intent to terminate the Pfizer Agreement. The Company’s right to receive these biosimilar royalty payments would survive a termination of the Pfizer Agreement.

For the three months ended March 31, 2012 and 2011, the Company recognized revenue of $365,000 and $551,000, respectively, for research and development services pursuant to the Pfizer Agreement in the Company’s financial statements of operations as contracts and grants revenue.